Aventiv Research Dublin — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$5,897	107
2023	Research	$8,312	8
2022	Research	$9,834	3
2020	Research	$29,581	5
2019	Research	$241,794	10

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca AB $182,114 4 payments
AstraZeneca Pharmaceuticals LP $80,061 10 payments
AbbVie, Inc. $13,049 6 payments
AstraZeneca UK Limited $9,200 1 payment
Boehringer Ingelheim International GmbH $5,628 106 payments
Pfizer Inc. $5,097 5 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $269 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS $182,114 4 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $62,194 3 payments
AZD2693, Cardiovascular, Renal and Metabolism $9,200 1 payment
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence $8,429 1 payment
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $8,072 4 payments
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease $6,779 1 payment
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $5,097 5 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $5,083 97 payments
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL. $3,083 2 payments
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial $3,016 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.